Качественная клиническая практика (Aug 2019)
Fixed and separate combination of solifenacin and tamsulosin in urinary disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison
Abstract
Objective. To determine the consequences of the use of a fi xed combination of solifenacin and tamsulosin in patients whom recommended the prescription of these drugs. Methods. Analysis of prices of drugs solifenacin + tamsulosin controlled release (Vasomni), solifenacin (Vesicare), tamsulosin controlled release (Omnic Okas) and tamsulosin modifi ed-release (several registered trade names of the drug) conducted on the basis of information from several sources: 1 — the register of maximum ex-works prices of manufacturers of vital and essential medicines, 2 — data on average prices in pharmacies of Moscow (as of 15.02.2018), 3 — weighted average prices of public procurement for 2018 according to the monitoring of the pharmaceutical market. To determine the points of relative value of drugs, a survey of experts was conducted: 1 — to determine the values of the criteria for the drugs under consideration — urologists; 2 — to determine the weight of the criteria — persons involved in the decision-making on the selection and purchase of drugs. Results. We found that the cost of the equivalent course dose of Vesomni was on 40-42 % lower than the combination of drugs Vesicar and Omnik Okas. Compared with the non-fi xed combination of solifenacin with tamsulosin in a drug form with modifi ed release, no signifi cant diff erences in price levels were found. At the same time, the relative value of a fi xed combination is 5-6 percentage points higher compared to non-fi xed combinations, mainly due to ease of use. Conclusion. Use of a fi xed combination of solifenacin + tamsulosin can lead to budget savings with an increase in the level of relative value.
Keywords
